Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells

Microvascular Research

Volumn 85, Issue 1, 2013, Pages 59-67

  Ren, Yonglin ^a   Guo, Liang ^a   Tang, Xiaoyan ^a   Apparsundaram, Subramaniam ^a   Kitson, Christopher ^a   Deguzman, Jeremy ^a   Fuentes, Maria E ^a   Coyle, Luke ^a   Majmudar, Rupal ^a   Allard, John ^a   Truitt, Theresa ^a   Hamid, Rachid ^a   Chen, Yun ^a   Qian, Yimin ^a   Budd, David C ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1 RECEPTOR; LYSOPHOSPHATIDIC ACID 2 RECEPTOR; LYSOPHOSPHATIDIC ACID 3 RECEPTOR; LYSOPHOSPHATIDIC ACID 4 RECEPTOR; LYSOPHOSPHATIDIC ACID 6 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MICROVASCULAR ENDOTHELIAL CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ARTERIES; CALCIUM; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LYSOPHOSPHOLIPIDS; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; PERMEABILITY; POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING; TIME FACTORS;

MURINAE;

EID: 84871716750     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.10.004     Document Type: Article

References (42)

1. Adkison J.B., et al. Differential responses of pulmonary endothelial phenotypes to cyclical stretch. Microvasc. Res. 2006, 71:175-184.
2. Beck H.P., et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg. Med. Chem. Lett. 2008, 18:1037-1041.
3. Birukov K.G., et al. Magnitude-dependent regulation of pulmonary endothelial cell barrier function by cyclic stretch. Am. J. Physiol. Cell Physiol. 2003, 285:L785-L797.
4. Birukova A.A., et al. Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling. Transl. Res. 2010, 155:44-54.
5. Burton V.J., et al. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 2011, 117:333-341.
6. Burton V.J., et al. Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. Blood 2011, 118:4750-4758.
7. Butcher A.J., et al. Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 2011, 286:11506-11518.
8. Butcher A.J., et al. Examining site-specific GPCR phosphorylation. Methods Mol. Biol. 2011, 746:237-249.
9. Castelino F.V., et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011, 63:1405-1415.
10. Chen S.U., et al. Lysophosphatidic acid mediates interleukin-8 expression in human endometrial stromal cells through its receptor and nuclear factor-kappaB-dependent pathway: a possible role in angiogenesis of endometrium and placenta. Endocrinology 2008, 149:5888-5896.
11. Chen R.J., et al. Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells. Int. J. Cancer 2012, 131:789-802.
12. Chesney J., et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 1998, 160:419-425.
13. Chetham P.M., et al. Segmental regulation of pulmonary vascular permeability by store-operated Ca2+ entry. Am. J. Physiol. 1999, 276:L41-L50.
14. Clements R.T., et al. RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am. J. Physiol. Cell Physiol. 2005, 288:L294-L306.
15. Dejana E., et al. The molecular organization of endothelial junctions and their functional role in vascular morphogenesis and permeability. Int. J. Dev. Biol. 2000, 44:743-748.
16. Fujiwara Y., et al. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J. Biol. Chem. 2005, 280:35038-35050.
17. Fujiwara A., et al. Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases. Respirology 2012, 17:693-698.
18. Gainor J.P., et al. Platelet-conditioned medium increases endothelial electrical resistance independently of cAMP/PKA and cGMP/PKG. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H1992-H2001.
19. Gebb S., Stevens T. On lung endothelial cell heterogeneity. Microvasc. Res. 2004, 68:1-12.
20. Hirakawa M., et al. Sequential activation of RhoA and FAK/paxillin leads to ATP release and actin reorganization in human endothelium. J. Physiol. 2004, 558:479-488.
21. 2+ and permeability. Am. J. Physiol. 1998, 274:L810-L819.
22. Lee H., et al. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. J. Physiol. Cell Physiol. 2000, 278:C612-C618.
23. Lucas R., et al. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem. Pharmacol. 2009, 77:1763-1772.
24. Medina A., Ghahary A. Fibrocytes can be reprogrammed to promote tissue remodeling capacity of dermal fibroblasts. Mol. Cell. Biochem. 2010, 344:11-21.
25. Mutoh T., et al. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 2012, 165:829-844.
26. Nitz T., et al. Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. Brain Res. 2003, 981:30-40.
27. Obernosterer G., et al. Target site effects in the RNA interference and microRNA pathways. Biochem. Soc. Trans. 2008, 36:1216-1219.
28. Oikonomou N., et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 10.1165/rcmb.2012-0004OC.
29. Qian Y., et al. Discovery of highly selective and orally active lysophosphatidic Acid receptor-1 antagonists with potent activity on human lung fibroblasts. J. Med. Chem. 2012, 55:7920-7939.
30. Qiu J., et al. Endothelial cell damage induces a blood-alveolus barrier breakdown in the development of radiation-induced lung injury. Asia Pac. J. Clin. Oncol. 2011, 7:392-398.
31. Sarker M.H., et al. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation 2010, 17:39-46.
32. Shea B.S., et al. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am. J. Respir. Cell Mol. Biol. 2010, 43:662-673.
33. Sun H., et al. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation 2006, 13:237-247.
34. Swaney J.S., et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 2010, 160:1699-1713.
35. Swaney J.S., et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 2011, 336:693-700.
36. Tager A.M., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 2008, 14:45-54.
37. 2+ channels and pulmonary endothelial permeability: insights from study of intact lung and chronic pulmonary hypertension. Microcirculation 2006, 13:725-739.
38. van Nieuw Amerongen G.P., et al. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler. Thromb. Vasc. Biol. 2000, 20:E127-E133.
39. Wong S.H., et al. Strategy for the identification of GPR23/LPA4 receptor agonists and inverse agonists. Assay Drug Dev. Technol. 2010, 8:459-470.
40. Yanagida K., et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 2009, 284:17731-17741.
41. Yin Q., et al. Alteration of tight junctions in pulmonary microvascular endothelial cells in bleomycin-treated rats. Exp. Toxicol. Pathol. 2012, 64:81-91.
42. Zaslavsky A., et al. Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochim. Biophys. Acta 2006, 1761:1200-1212.